HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Diabetes Care

• Publication date

  2014-06-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/dc14-0024PMID 24898304
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

  2014cited by this paper
• Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

  2014cited by this paper
• Real‐world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review

  2013cited by this paper
• Longitudinal association between medication adherence and glycaemic control in Type 2 diabetes

  2013cited by this paper
• Standards of Medical Care in Diabetes—2014

  2013cited by this paper
• Albiglutide: clinical overview of a long-acting GLP-1 receptor agonist in the treatment of Type 2 diabetes

  2013cited by this paper
• Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial

  2013cited by this paper
• Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2013cited by this paper
• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2012cited by this paper
• DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.

  2012cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012cited by this paper
• Patient adherence to medication requirements for therapy of type 2 diabetes

  2011cited by this paper
• Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.

  2010cited by this paper
• Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes

  2010cited by this paper
• Standards of medical care in diabetes--2007.

  2009cited by this paper
• Standards of Medical Care in Diabetes—2009

  2009cited by this paper
• Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes

  2009cited by this paper
• Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004.

  2008cited by this paper
• Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.

  2008cited by this paper
• Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

  2008cited by this paper
• Standards of medical care in diabetes.

  2006cited by this paper
• Standards of Medical Care in Diabetes: Response to Power

  2006cited by this paper
• Improvements in Diabetes Processes of Care and Intermediate Outcomes: United States, 19882002

  2006cited by this paper
• Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.

  2005cited by this paper
• Variations in Patients’ Adherence to Medical Recommendations: A Quantitative Review of 50 Years of Research

  2004cited by this paper
• A systematic review of adherence with medications for diabetes.

  2004cited by this paper

• Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies.

  2026cites this paper
• Suicide and Self-Harm Events With GLP-1 Receptor Agonists in Adults With Diabetes or Obesity: A Systematic Review and Meta-Analysis.

  2025cites this paper
• Long-Term Efficacy Trajectories of GLP-1 Receptor Agonists: A Systematic Review and Network Meta-Analysis

  2025cites this paper
• The Ozempic Generation: What the Interventional Radiologist Needs to Know About GLP‐1 Agonists

  2025cites this paper
• Efficacy and Safety of Tirzepatide Compared with GLP-1 RAs in Patients with Type 2 Diabetes Treated with Basal Insulin: A Network Meta-analysis

  2025cites this paper
• Cardiovascular Events and Heart Failure in Patients With Type 2 Diabetes Treated With Dipeptidyl Peptidase-4 Inhibitors: A Meta-Analysis

  2025cites this paper
• Novel Antidiabetic Drugs and the Risk of Diabetic Retinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2024cites this paper
• The weight reduction mediated by anti-obesity medication and the cardiovascular outcome

  2024cites this paper
• Efficacy and safety of albiglutide, a once-weekly glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes: A systematic review and meta-analysis

  2024cites this paper
• Research Advances in Fusion Protein-Based Drugs for Diabetes Treatment

  2024cites this paper
• Association of Glucagon-like peptide-1 receptor agonists use with fracture risk in type 2 diabetes: A meta-analysis of randomized controlled trials.

  2024cites this paper
• Towards Optimal Cardiovascular Health: A Comprehensive Review of Preventive Strategies

  2024cites this paper
• Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians

  2024cites this paper
• Inkretin-Agonisten: In 30 Jahren vom Geheimtipp zum Bestseller

  2023cites this paper
• Association of SLC22A1, SLC47A1, and KCNJ11 polymorphisms with efficacy and safety of metformin and sulfonylurea combination therapy in Egyptian patients with type 2 diabetes

  2023cites this paper
• The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials

  2023cites this paper
• Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review

  2023cites this paper
• Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach

  2023cites this paper
• Saudi Consensus for Oral Semaglutide, the Recent Innovation in GLP-1 RAs Era; Consensus Report

  2023cites this paper
• Effects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes

  2023cites this paper
• Is the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes?

  2023cites this paper
• Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials

  2022cites this paper
• The effectiveness and value of tirzepatide for type 2 diabetes mellitus

  2022cites this paper
• Drug‐associated acquired hemophilia A: an analysis based on 185 cases from the WHO pharmacovigilance database

  2022cites this paper
• Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials

  2022cites this paper
• Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials

  2022cites this paper
• Enhancing Night and Day Circadian Contrast through Sleep Education in Prediabetes and Type 2 Diabetes Mellitus: A Randomized Controlled Trial

  2022cites this paper
• Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs

  2022cites this paper
• Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease

  2022cites this paper
• The Position of Gliclazide in the Evolving Landscapes and Disease Continuum of T2DM: A Collaborative Delphi Survey-Based Consensus from India

  2021cites this paper
• Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials

  2021cites this paper
• Changing the approach to type 2 diabetes treatment: A comparison of glucagon‐like peptide‐1 receptor agonists and sulphonylureas across the continuum of care

  2021cites this paper
• Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review

  2021cites this paper
• Prevention of type 1 diabetes: where we are and where we are going.

  2021cites this paper
• Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas

  2021cites this paper
• Choosing Medications for Weight Loss in Type 2 Diabetes Mellitus

  2021cites this paper
• Les sulfamides hypoglycémiants gardent toujours une place dans le traitement du diabète de type 2 en 2021. Les points forts du dossier des sulfamides hypoglycémiants

  2021cites this paper
• Tinjauan atas Glucagon-like peptide-1 receptor agonist

  2020cites this paper
• GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus.

  2020cites this paper
• Durability of glycaemic control in type 2 diabetes: A systematic review and meta‐analysis for its association with body weight changes

  2020cites this paper
• Potential cardiovascular benefits of GLP-1 analogues: evidence and implications for type 2 diabetes management

  2020cites this paper
• Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus

  2020cites this paper
• Risk of sudden cardiac arrest and ventricular arrhythmia with sulfonylureas: An experience with conceptual replication in two independent populations

  2020cites this paper
• Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial

  2020cites this paper
• Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis

  2020cites this paper
• Cardiovascular safety and efficacy of combination therapy with metformin and sodium-glucose cotransporter-2 inhibitors versus metformin and sulfonylureas in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

  2020cites this paper
• GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials

  2020cites this paper
• Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.

  2020cites this paper
• Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials.

  2020cites this paper
• Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon‐Like Peptide‐1 Receptor Agonist and Sodium‐Glucose Cotransporter‐2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta‐Analysis

  2020cites this paper
• Effect of insulin secretagogues on major cardiovascular events and all-cause mortality: A meta-analysis of randomized controlled trials.

  2020cites this paper
• Drug-Induced Cough.

  2020cites this paper
• Antidiabetic Medications and the Risk of Prostate Cancer in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis.

  2020cites this paper
• Random‐effects meta‐analysis of combined outcomes based on reconstructions of individual patient data

  2020cites this paper
• Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-Analysis

  2020cites this paper
• Drug-induced chronic cough and the possible mechanism of action.

  2020cites this paper
• Potential cardiovascular benefits of GLP-1 analogues : evidence and implications for type 2 diabetes management

  2020cites this paper
• Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials.

  2020cites this paper
• Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement

  2019cites this paper
• Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.

  2019cites this paper
• Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus.

  2019cites this paper
• Efficacy of the Modern SU Glimepiride in Reducing Hyperglycemia in T 2 DM

  2019cites this paper
• DPP-4 Inhibition and the Path to Clinical Proof

  2019cites this paper
• Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study.

  2019cites this paper
• Predictive factors associated with three years of response to HbA1c goals with exenatide QW or insulin glargine: Post‐hoc analysis of the DURATION‐3 study

  2019cites this paper
• PANCREATIC SAFETY IN STUDIES OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ALBIGLUTIDE.

  2019cites this paper
• Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis

  2019cites this paper
• Central Glucagon-like Peptide-1 Receptor Signaling via Brainstem Catecholamine Neurons Counteracts Hypertension in Spontaneously Hypertensive Rats

  2019cites this paper
• Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes.

  2019cites this paper
• A Model‐Based Meta‐Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses

  2019cites this paper
• GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials

  2019cites this paper
• Comparative effectiveness of once‐weekly glucagon‐like peptide‐1 receptor agonists with regard to 6‐month glycaemic control and weight outcomes in patients with type 2 diabetes

  2018cites this paper
• Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia

  2018cites this paper
• Glucagon-like peptide 1 in health and disease

  2018cites this paper
• Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis

  2018cites this paper
• A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Anti-Diabetic Drugs

  2018cites this paper
• Real-world comparison of treatment patterns and effectiveness of albiglutide and liraglutide.

  2018cites this paper
• Comparisons of diabetic retinopathy events associated with glucose‐lowering drugs in patients with type 2 diabetes mellitus: A network meta‐analysis

  2018cites this paper
• Tratamiento con agonistas del receptor del GLP-1 en pacientes con Diabetes Mellitus Tipo 2 en la práctica clínica habitual

  2018cites this paper
• Are there differences in the efficacy of once-weekly GLP-1RAs in patients with type 2 diabetes?

  2018influential citation
• Battle of GLP-1 delivery technologies.

  2018cites this paper
• Risk of dipeptidyl peptidase‐4 (DPP‐4) inhibitors on site‐specific cancer: A systematic review and meta‐analysis

  2018cites this paper
• GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes

  2018cites this paper
• Effects on repetitive 24-hour ambulatory blood pressure in subjects with type II diabetes randomized to liraglutide or glimepiride treatment both in combination with metformin: a randomized open parallel-group study.

  2018cites this paper
• Observational studies of treatment effectiveness: worthwhile or worthless?

  2018cites this paper
• Safety of once-weekly glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes

  2018influential citation
• HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.

  2018cites this paper
• Recent updates on GLP-1 agonists: Current advancements & challenges.

  2018cites this paper
• Incretin‐based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials

  2018cites this paper
• A review of GLP‐1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials

  2018cites this paper
• Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus – International Task Force

  2018cites this paper
• Clinical and Investigative Endocrinology and Diabetes.

  2018cites this paper
• Efficacy of glucagon‐like peptide‐1 receptor agonists compared to dipeptidyl peptidase‐4 inhibitors for the management of type 2 diabetes: A meta‐analysis of randomized clinical trials

  2018cites this paper
• Albiglutide for the management of type 2 diabetes

  2018cites this paper
• Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus

  2018cites this paper
• Glucagon-Like Peptide 1 Receptor Agonists For Type 2 Diabetes: A Comprehensive Review of How to Weigh The Options, Select the Right Patients, and Maximize Benefits

  2018cites this paper
• Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis.

  2018cites this paper
• Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?

  2018cites this paper
• Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs

  2017cites this paper
• Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?

  2017cites this paper